Sun Pharmaceutical Industries Limited reported a consolidated net profit of ₹28,948 million for Q1FY27, rising year-on-year despite a 9.7% decline in US sales. The Mumbai-based pharma major posted revenue of ₹151,836 million, marking a 10.1% increase over the previous quarter. Strong performance in the domestic market, where sales grew 16%, and robust expansion in its innovative medicines portfolio offset headwinds in the US generics segment. The company also highlighted progress in its Organon acquisition, which is on track to close by early 2027.

Financial Performance

Consolidated revenue reached ₹151,836 million in Q1FY27, up from ₹138B in Q1FY26. Gross margin improved to 80.5%, driven by a better product mix with higher contributions from branded generics and innovative medicines. EBITDA stood at ₹44,177 million, a 2.7% increase year-on-year, with margins holding steady at 28.9%. CFO Jayashree Satagopan noted that adjusted EBITDA margins were higher than the prior year when excluding one-time benefits from Lenalidomide sales in Q1FY26.

Reported net profit after tax was ₹28,948 million, while adjusted net profit was ₹30,894 million. The effective tax rate (ETR) rose to 27.8% from 24.3% in Q1FY26, primarily due to the exhaustion of lower tax rates in India and varying rates across global jurisdictions. Exceptional items included a ₹1,617 million charge for Organon acquisition-related costs.

Regional Business Updates

The India business emerged as a key growth driver, with formulation sales reaching ₹54,749 million, a 16% year-on-year increase. This accounted for 36.1% of total consolidated sales. Sun Pharma reported a 5.4% volume growth, outperforming the industry average of 2%. The company secured the number 2 position for generic semaglutide injectables in India and holds an 8.5% market share in the domestic pharmaceutical sector.

In contrast, US sales declined 9.7% to USD 427 million. CEO North America Richard Ascroft attributed the drop to erosion in Lenalidomide sales and increased competition in certain generic products. However, the innovative medicines portfolio in the US grew, supported by launches like Leqselvi and Unloxcyt. Leqselvi surpassed 1,000 prescribers in June, while Unloxcyt gained traction in cancer centers due to its differentiated safety profile.

Emerging markets revenue was USD 311 million, up 4.2% year-on-year, while Rest of World (ROW) revenue remained flat at USD 218 million. Geopolitical issues and macroeconomic conditions impacted growth in some emerging economies.

Strategic Developments

Sun Pharma continues to advance its R&D pipeline, spending ₹8,264 million (5.4% of sales) in Q1FY27, with 30% allocated to innovative medicines. The company received approvals to manufacture generic semaglutide injection in Brazil and South Africa, with launches underway. Additionally, partner Philogen has resubmitted Nidlegly for marketing authorization in Europe.

The Organon acquisition process is nearing completion, with regulatory filings done in various markets and shareholder approval secured. An integration management office is preparing for day-one readiness, expecting closure in Q4FY27. The balance sheet remains strong with net cash of USD 3.4 billion at the consolidated level.

Sun Pharmaceutical Industries Limited has announced a schedule of upcoming analyst and institutional investor meetings to be held in Mumbai during August 2026. The company will engage with market participants through both group and one-on-one sessions at three major financial conferences. This disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparency regarding management’s interaction with the investment community.

The meetings are scheduled across three dates in early August, allowing analysts and investors to discuss business outlooks and industry trends. Sun Pharmaceutical Industries Limited emphasized that no Unpublished Price Sensitive Information (UPSI) will be disclosed at any of these events. The schedule remains subject to change due to exigencies on either side.

Meeting Schedule

The following table outlines the confirmed engagements:

Compliance Details

The intimation was signed by Anoop Deshpande, Company Secretary and Compliance Officer of Sun Pharmaceutical Industries Limited. The disclosure was filed on August 05, 2026, with the National Stock Exchange of India Limited and BSE Limited. The company reaffirmed its commitment to regulatory compliance by explicitly stating that all interactions would adhere to SEBI guidelines regarding information symmetry.